Cereno Scientific is granted Orphan Medicinal Product Designation in the EU for CS1 in rare disease Pulmonary Arterial Hypertension
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the European Commission has granted Orphan Medicinal Product Designation (OMPD) to the Company’s lead drug candidate CS1 in the rare disease Pulmonary Arterial Hypertension (PAH).“I am very pleased to report that CS1 has been granted Orphan Medicinal Product Designation (OMPD) in the EU, covering all 27 EU countries. This designation offers significant advantages, including a 10-year market exclusivity period post-